IQVIA (IQV) Stock
Fundamentals
Recent news

IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know
IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know
IQV

Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term
Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term
IQV

IQVIA Announces Pricing of Senior Notes
IQVIA Announces Pricing of Senior Notes
IQV

IQVIA Announces Offering of Senior Notes
IQVIA Announces Offering of Senior Notes
IQV
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $2.74 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know
IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know
IQV

Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term
Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term
IQV

IQVIA Announces Pricing of Senior Notes
IQVIA Announces Pricing of Senior Notes
IQV

IQVIA Announces Offering of Senior Notes
IQVIA Announces Offering of Senior Notes
IQV

IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster
IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster
IQV

IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
IQV

Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?
Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?
IQV

Here's Why You Should Retain IQVIA Stock in Your Portfolio Now
Here's Why You Should Retain IQVIA Stock in Your Portfolio Now
IQV

IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year
IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year
IQV

IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group
IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group
IQV
About IQVIA
IQVIA is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Ari Bousbib | CEO & Chairman | 1961 |
| Mr. Eric M. Sherbet J.D. | Executive VP, General Counsel & Secretary | 1964 |
| Mr. W. Richard Staub III | President of Research & Development Solutions | 1963 |
| Mr. Alistair Grenfell | President of Commercial Solutions | 1974 |
| Mr. Michael J. Fedock MBA | Executive VP & Chief Financial Officer | 1976 |
| Mr. James G. Berkshire | Executive Vice President of Global Infrastructure & Operations | 1974 |
| Ms. Keriann Cherofsky | Senior VP, Corporate Controller & Chief Accounting Officer | 1985 |
| Dr. Jeffrey A. Spaeder M.D. | Chief Medical & Scientific Officer | — |
| Kerri Joseph | Senior VP of Investor Relations & Treasurer | — |
| Mr. Duane Sachs | Senior Vice President of Corporate Development | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
8 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -1.4 | +8.2 | +0.1 | +8.8 | ||||||||
| 2022 | -10.5 | -6.9 | +1.5 | -9.3 | -0.8 | +3.3 | +11.7 | -10.8 | -14.4 | +12.6 | +4.1 | -7.1 |
| 2023 | +12.5 | -10.7 | -5.6 | -5.9 | +3.6 | +13.0 | +1.2 | +1.6 | -12.3 | -6.7 | +18.9 | +6.7 |
| 2024 | -9.6 | +17.0 | +0.2 | -6.9 | -5.9 | -2.3 | +18.1 | +1.3 | -4.8 | -11.0 | -4.0 | -2.6 |
| 2025 | +3.2 | -5.2 | -4.6 | -9.4 | -7.1 | +13.3 | +14.3 | +4.6 | +3.4 | +6.2 | +7.5 | -1.3 |
| 2026 | +2.1 | -22.7 | -2.1 | -8.1 | +15.5 | +3.4 | +15.7 | +11.9 | +4.7 |



